MX2021007142A - Compuestos organicos. - Google Patents

Compuestos organicos.

Info

Publication number
MX2021007142A
MX2021007142A MX2021007142A MX2021007142A MX2021007142A MX 2021007142 A MX2021007142 A MX 2021007142A MX 2021007142 A MX2021007142 A MX 2021007142A MX 2021007142 A MX2021007142 A MX 2021007142A MX 2021007142 A MX2021007142 A MX 2021007142A
Authority
MX
Mexico
Prior art keywords
methods
organic compounds
methoxymethy
pregnan
anxiolytics
Prior art date
Application number
MX2021007142A
Other languages
English (en)
Inventor
Peng Li
Kimberly Vanover
Robert Davis
Yupu Qiao
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2021007142A publication Critical patent/MX2021007142A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/007—Steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

La invención se refiere a profármacos y análogos particulares de (3a,5a)-3-hidroxi-21-(1H-imidazol-1-il)-3-metoximetil)-pregnan-20 -ona, en forma libre o de sal farmacéuticamente aceptable y/o sustancialmente pura como se describe en la presente, composiciones farmacéuticas de los mismos y métodos de uso como sedantes, hipnóticos, ansiolíticos y/o anestésicos, y métodos para el tratamiento de la depresión, ansiedad, insomnio, epilepsia y otros trastornos del sistema nervioso central, así como combinaciones con otros agentes.
MX2021007142A 2018-12-17 2019-12-17 Compuestos organicos. MX2021007142A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862780703P 2018-12-17 2018-12-17
PCT/US2019/066923 WO2020131918A1 (en) 2018-12-17 2019-12-17 Organic compounds

Publications (1)

Publication Number Publication Date
MX2021007142A true MX2021007142A (es) 2021-08-11

Family

ID=71100855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007142A MX2021007142A (es) 2018-12-17 2019-12-17 Compuestos organicos.

Country Status (11)

Country Link
US (1) US20220073558A1 (es)
EP (1) EP3897656A4 (es)
JP (1) JP2022513933A (es)
KR (1) KR20210105934A (es)
CN (1) CN113226326A (es)
AU (1) AU2019406803A1 (es)
BR (1) BR112021011765A2 (es)
CA (1) CA3121636A1 (es)
IL (1) IL283960A (es)
MX (1) MX2021007142A (es)
WO (1) WO2020131918A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
EP4200312A1 (en) * 2020-08-20 2023-06-28 Intra-Cellular Therapies, Inc. Organic compounds
WO2023159094A2 (en) * 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177206A1 (en) * 1999-04-29 2002-02-06 Purdue Pharma Ltd. 3alpha-hydroxy-3beta methoxymethyl-21-heterocycle substituted steroids with anaesthetic activity
US20060074059A1 (en) * 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
ES2344313T3 (es) * 2005-06-09 2010-08-24 Euro-Celtique S.A. Composiciones farmaceuticas de un esteroide neuroactivo y usos de las mismas.
NZ731034A (en) * 2014-10-16 2024-02-23 Sage Therapeutics Inc Compositions and methods for treating cns disorders
US10329320B2 (en) * 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
KR20200096596A (ko) * 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체

Also Published As

Publication number Publication date
CN113226326A (zh) 2021-08-06
JP2022513933A (ja) 2022-02-09
EP3897656A1 (en) 2021-10-27
BR112021011765A2 (pt) 2021-08-31
CA3121636A1 (en) 2020-06-25
KR20210105934A (ko) 2021-08-27
US20220073558A1 (en) 2022-03-10
IL283960A (en) 2021-07-29
AU2019406803A1 (en) 2021-07-08
WO2020131918A1 (en) 2020-06-25
EP3897656A4 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
MX2019014974A (es) Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson.
MX2022003323A (es) Polinucleotidos dirigidos al sistema nervioso central.
MX2018004755A (es) Entrega de polinucleotidos dirigidos al sistema nervioso central.
MX2021007142A (es) Compuestos organicos.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
MX359882B (es) Amidas como moduladores de canales de sodio.
TN2016000238A1 (en) Tricyclic compounds as anticancer agents.
JOP20170067B1 (ar) معدِّلات مختلفة الشكل الفراغي لمستقبلات أسيتيل كولين النيكوتينية
CL2011002206A1 (es) Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras.
IN2014DN09804A (es)
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MX2012009079A (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2018004220A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2021002322A (es) Nuevos metodos.